RJA
BNGO icon

Raymond James & Associates’s Bionano Genomics BNGO Stock Holding History

Raymond James & Associates’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19
Closed -$62K – 4145
2021
Q3 		$62K Sell
19
-4
-17% -$14K ﹤0.01% 3894
2021
Q2 		$102K Sell
23
-8
-26% -$31.6K ﹤0.01% 3832
2021
Q1 		$151K Buy
+31
New +$175K ﹤0.01% 3692

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Raymond James & Associates's BNGO Position: Q4 2021 in Review

Raymond James & Associates sold out of Bionano Genomics (BNGO) in Q4 2021, closing a stake of 19 shares — an estimated $62K sold.

Raymond James & Associates first reported a position in BNGO in Q1 2021 and held it in 3 quarters. The position peaked at $151K in Q1 2021. 149 funds tracked by Wall St. Rank hold BNGO as of Q4 2021.

  • Raymond James & Associates reported no remaining Bionano Genomics position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 19 Bionano Genomics shares in Q4 2021, an estimated $62K.
  • Raymond James & Associates first reported a position in Bionano Genomics in Q1 2021 and held it in 3 quarters.
  • Raymond James & Associates's Bionano Genomics position peaked at $151K in Q1 2021.
  • 149 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.